AMENDMENTS TO THE CLAIMS

In the claims, please cancel claim 17 and amend claims 14, 16, and 23 as follows:

1-13. (canceled)

14. (currently amended) A process for delivery of a polynucleotide to a cell comprising:
   a) forming a complex consisting of a polynucleotide and a primary amine-containing polycationic molecule;
   b) adding a chelator capable of forming a non-covalent coordinate bond with a primary amine to the complex of a) to form a new complex wherein the chelator forms a non-covalent coordinate bond with the primary amine on the primary amine-containing polycationic molecule; and,
   c) delivering the new complex to the cell.

15. (previously presented) The process of claim 14 wherein the chelator consists of a crown ether.

16. (currently amended) The process of claim 14 wherein the primary amine-containing polycationic molecule is a polyamine.

17. (canceled)

18. (previously presented) The process of claim 14 wherein the chelator consists of a polychelator.

19. (previously presented) The process of claim 18 wherein the polychelator consists of a polyanion.

20. (previously presented) The process of claim 19 wherein the polyanion recharges the complex to give the complex a negative surface charge.

21. (previously presented) The process of claim 18 wherein the polychelator consists of a polycation.

22. (previously presented) The process of claim 14 wherein the chelator is covalently linked to a compound selected from the list consisting of: a cell targeting signal, a releasing signal, and a hydrophobic group.

23. (currently amended) The process of claim 14 wherein the primary amine-containing polycationic molecule is selected from the list consisting of: a cell receptor signal, a releasing signal, a hydrophobic group and a steric stabilizer.

24. (previously presented) The process of claim 14 wherein the polynucleotide is expressible.

25. (previously presented) The process of claim 24 wherein the polynucleotide expresses a therapeutic gene.

26. (previously presented) The process of claim 14 wherein the cell consists of an *in vivo* mammalian cell.